To the full analysis
GE HealthCare Technologies stock: growth
GEHCGE HealthCare Technologies reported $20.63B in revenue for fiscal 2025, up 4.8% on the prior year, up 3.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
3.7%
per year from 2019 to 2025, per share 3.6%
Earnings (Annual rate)
5.4%
per year from 2019 to 2025, per share 5.3%
Free cash flow (Annual rate)
−1.6%
per year from 2019 to 2025, per share −1.7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2019 | |
|---|---|---|
| Revenue | 3.7% | 3.7% |
| Revenue per share | 3.7% | 3.6% |
| Earnings | −31.5% | 5.4% |
| Earnings per share | 0.7% | 5.3% |
| Free cash flow | 1.1% | −1.6% |
| Free cash flow per share | 1.0% | −1.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $16.63B | $1.52B | $1.66B |
| 2020 | $17.16B | $13.85B | $1.43B |
| 2021 | $17.59B | $2.25B | $1.36B |
| 2022 | $18.34B | $1.92B | $1.8B |
| 2023 | $19.55B | $1.57B | $1.71B |
| 2024 | $19.67B | $1.99B | $1.55B |
| 2025 | $20.63B | $2.08B | $1.51B |
Revenue by region
Where GE HealthCare Technologies Inc. generates its revenue.
- United States44%
- China10%
- Other46%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| United States | $8.23B | $8.62B | $9.17B | 44.5% |
| China | $2.56B | $2.14B | $2.03B | 9.8% |
| Other | $8.76B | $8.92B | $9.43B | 45.7% |
| Total revenue | $19.55B | $19.67B | $20.63B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Sep 2026)
- Valuation signal Undervalued since 11 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.